Chromosomal Instability Associated with Improved Outcomes in Breast Cancer
the Cancer Therapy Advisor take:
There is an association between extreme chromosomal instability and improved outcome in estrogen receptor (ER)-negative breast cancers, a new study published online early in the journal Annals of Oncology has shown.
Previous studies have shown that extreme chromosomal instability is associated with improved clinical outcome in patients with ER-negative breast cancer, while it has been shown to be linked with drug resistance and poor outcomes in various other cancers.
For this study, researchers analyzed 1,173 tumors form the breast cancer TACT trial by performing dual centromeric fluorescence in situ hybridization for chromosomes 2 and 15.
Results showed that during a median follow-up of 91 months, extreme chromosomal instability was associated with improved clinical outcome in patients with ER-negative breast cancer (P trend = 0.03). In addition, researchers found that increasing chromosomal instability was associated with improved outcome in patients with ER-negative/HER2-negative breast cancers (P trend = 0.007).
Identifying patients with extreme chromosomal instability may help to predict prognosis and guide treatment decisions.
Association between extreme chromosomal instability and improved outcome in ER-negative breast cancers.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Pancreatitis and the Risk of Cancer
- RAMIE May Improve Post-operative Outcomes Among Patients With Esophageal Cancer
- Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery Prolongs OS in Gastric Cancer
- Renal Cell Carcinoma: Cost of Treatment May Negate Impact of Treatment Advances
- Pembrolizumab May Be Effective for Previously Treated Hepatocellular Carcinoma
- CTC Screening May Be Effective Method for Preventing Colorectal Cancer
- Physical Activity Intervention May Improve Functional Well-being Among CRC Survivors
- Atezolizumab With Cobimetinib Yields Partial Response in Small Number of Patients With CRC
- Nivolumab May Improve Long-term Complete Response Rate in Subset of Patients With mCRC
- Alcohol Consumption and Cancer